GILD vs KROS · P/E 18, rev $7.80B vs rev $32.0K
Gilead Sciences Inc (GILD) versus Keros Therapeutics Inc (KROS) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. KROS currently screens at market cap $208.8M.
Not investment advice. Open the GILD and KROS stock pages for the full models.
Not investment advice.